Cyclo TherapeuticsNASDAQ: CYTH

Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.29 per share a year ago.

MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its transaction with Rafael Holdings. Click here to learn how to join our investigation https://www.ademilaw.com/case/cyclo-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

NEW YORK , Aug. 22, 2024 /PRNewswire/ --  Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Cyclo Therapeutics, Inc. (Nasdaq: CYTH), relating to its proposed merger with Rafael Holdings, Inc. Under the terms of the agreement, Cyclo common stock will automatically be converted into the right to receive shares of Rafael common stock.

Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.33 per share a year ago.

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the last patient has been enrolled in the Company's pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol® Cyclo™ for the treatment of systemic and neurological symptoms of Niemann-Pick Disease.